Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial)

Authors:

Abstract
No abstract available
Funding Information
  • Novo Nordisk

This publication has 21 references indexed in Scilit: